Researchers have hypothesized that the combination of CJC-1295 and GHRP-6 may have a synergistic impact on cells that contribute to producing growth hormones. The blend comprises GHRP-6 (Growth Hormone hormone-releasing peptide 6), which studies suggest binds to the receptors of the hunger hormone ghrelin, and CJC-1295, which seems to behave similarly to the growth hormone-releasing hormone (GHRH).
Research suggests that this peptide blend might potentially enhance the potency and frequency with which somatotroph cells trigger growth hormone release. Findings imply that since CJC-1295 seems to target the GHRH receptor pathway and GHRP-6 is speculated to work on the ghrelin receptor pathway, these two compounds may likely have a synergistic impact. For this reason, the synergistic effects of CJC-1295 and GHRP-6 on somatotroph cells in the pituitary gland and hypothalamus may be speculated. Both brain areas are thought to include cells critical to producing and regulating growth hormones.
Compound Structure of GHRP-6 and CJC-1295
Synthetically created peptide CJC-1295, known as tetra-substituted GRF (1-29), is bioequivalent to the naturally occurring GHRH hormone. It comprises the first 29 amino acids of GHRH, the shortest conceivable chain that might interact with GHRH receptors. CJC-1295 is structurally similar to the naturally occurring GHRH analog, but 4 of the original 29 amino acids are replaced with substituted versions. Investigations purport that this substitution may increase the peptide’s stability against degradation by dipeptidyl peptidase-4. The second, eighth, fifteenth, and twenty-seventh amino acids have all been changed and replaced.[i] It was also hypothesized that “CJC-1295 may have caused a rise in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry data.” The GHRH receptor in the anterior pituitary seems to be a target for CJC-1295. Potentially, it may help keep the growth hormone (GH) production going strong and boost overall physiological levels [ii].
The peptide Met-enkephalin has an opioid analog called GRHP-6. However, studies have suggested that it possibly may not exhibit the same opioid-like impacts as these enkephalins are often considered to have.[iii] Scientists classify GHRP-6, a synthetic hexapeptide, as a hormone-releasing peptide. Investigations purport that it may exert its possible effect via binding to the ghrelin receptor expressed by certain pituitary cells and a subset of hypothalamic neurons. Growth hormone secretagogue receptor 1a (GHS-R1a) seems activated upon binding with GHRP-6. As a result, research has been conducted into how it communicates with the receptor for growth hormone secretagogue. Researchers speculate that GHRP-6 seems to stimulate growth hormone release by molecularly mimicking the hormone ghrelin. Many cell types have growth hormone receptors, suggesting that GHRP-6’s potential might be systemic. [iv]
CJC-1295 and GHRP-6 Peptide Blend
Studies suggest that growth hormone (GH) is released from specialized sacs inside somatotroph cells once CJC-1295 attaches to them. Research suggests this peptide might increase growth hormone synthesis in these cells, leading to “GH concentrations by 2- to 10-fold.”[v] In addition, the growth hormone surge seems to be long-lasting enough to lead to a possible rise in some of the hormone’s primary anabolic mediators, such as so-called insulin-like growth factor 1 (IGF-1). The effects of CJC-1295 on test models have been discussed in another study, which suggests a rise of 46% in mean growth hormone levels and 45% in mean IGF-1 levels.[vi]
Data from experimental studies of GRHP-6 suggests the compound has exhibited positive potential in the research studies involving several cancer types. Studies on the GHRP-6 peptide have mostly focused on the peptide’s impact within the context of growth hormone-deficiencies, MOF, cachexia/wasting, and obesity.[vii]
Additionally, GHRP-6 may exhibit a selective binding affinity for CD36 receptors. These CD36 receptors may be involved in several processes, including lipid metabolism, lipid collection, immune response modification, particle uptake regulation, and inflammatory management. CD36 signaling pathways may also play a role in regulating blood vessel development.[viii]However, these theories need more research. Since GHRP-6 seems to have cytoprotective characteristics, it has been recommended for use in investigations of myocardial infarction in the hopes that it may lessen scarring in tissues that have undergone reperfusion.
These peptides appear to exhibit some synergistic action when presented together, perhaps elevating growth hormone levels to effect desired changes. In contrast to CJC-1295, which seems to induce a pulsatile release of the growth hormone primarily, GHRP-6 appears to maintain a baseline level of the hormone. However, it has been theorized that both peptides may favorably influence changes in sleep cycles. The majority of an organism’s development and repair happens during sleep or rest phases. Therefore, findings imply that this peptide blend might be useful for facilitating this process. Investigations purport that regulating sleep cycles may hasten wound healing and preserve delicate nerve tissue.
Visit Biotech Peptides’ blog for more educational information, like the one in this article.
References
[u] Scarborough R, Gulyas J, Schally AV, Reeves JJ. Analogs of growth hormone-releasing hormone induce release of growth hormone in the bovine. J Anim Sci. 1988 Jun;66(6):1386-92. doi: 10.2527/jas1988.6661386x. PMID: 3135287.
[ii] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.
[iii] Rico M, Lorenzo MT, Pazo JA, Vega FV, De la Cruz LF. GHRP-6 in heifer and cow adenohypophisial cells separated by elutriation. J Physiol Biochem. 1999 Mar;55(1):33-9. PMID: 10494658.
[iv] Martínez R, Hernández L, Gil L, Carpio Y, Morales A, Herrera F, Rodríguez-Mallón A, Leal Y, Blanco A, Estrada MP. Growth hormone releasing peptide-6 enhanced antibody titers against subunit antigens in mice (BALB/c), tilapia (Oreochromis niloticus) and African catfish (Clarias gariepinus). Vaccine. 2017 Oct 9;35(42):5722-5728. doi: 10.1016/j.vaccine.2017.07.060. PMID: 28893476.
[v] Teichman, Sam L., et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” The Journal of Clinical Endocrinology & Metabolism 91.3 (2006): 799-805.
[vi] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654.
[vii] Fujitsuka N, Asakawa A, Uezono Y, Minami K, Yamaguchi T, Niijima A, Yada T, Maejima Y, Sedbazar U, Sakai T, Hattori T, Kase Y, Inui A. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl Psychiatry. 2011 Jul 26;1(7):e23. doi: 10.1038/tp.2011.25. PMID: 22832525; PMCID: PMC3309517.
[viii] Demers A, McNicoll N, Febbraio M, Servant M, Marleau S, Silverstein R, Ong H. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J. 2004 Sep 1;382(Pt 2):417-24. doi: 10.1042/BJ20040036. PMID: 15176951; PMCID: PMC1133797.
